Campaign ledgers that record insecticide-treated net distribution frequently carry geocoding errors, and these errors are not independent of the healthcare access they are used to evaluate. The design is a before-after-control-impact (BACI) estimator with between-cluster standard deviation 6.0, residual standard deviation 4.5 and intraclass correlation 0.64; power was estimated across 2000 replications per design cell for cluster counts of 8, 16, 24 and 32 and effect sizes of 3, 5 and 8 percentage points. The analysis is methodological and uses no observational data: it reports the operating characteristics of the proposed design rather than an estimated effect on malaria incidence. Under the declared variance structure, 54 clusters are required to detect a 5 percentage point effect at 80 per cent power, and the minimum detectable effect falls steeply as cluster count rises from 8 to 32. The framework proposes that targeting-equity claims drawn from campaign ledgers are defensible only when the geocoding-error mechanism is modelled explicitly and the design is powered for the smallest effect the equity claim requires.
No takes yet. Share an insight, caveat, or question.
Amukoto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: